vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Smith Douglas Homes Corp. (SDHC). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $260.4M, roughly 1.9× Smith Douglas Homes Corp.). Smith Douglas Homes Corp. runs the higher net margin — 1.4% vs -10.1%, a 11.5% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -9.4%). Smith Douglas Homes Corp. produced more free cash flow last quarter ($8.7M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 17.3%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.

CLOV vs SDHC — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.9× larger
CLOV
$487.7M
$260.4M
SDHC
Growing faster (revenue YoY)
CLOV
CLOV
+54.1% gap
CLOV
44.7%
-9.4%
SDHC
Higher net margin
SDHC
SDHC
11.5% more per $
SDHC
1.4%
-10.1%
CLOV
More free cash flow
SDHC
SDHC
$77.7M more FCF
SDHC
$8.7M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
17.3%
SDHC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
SDHC
SDHC
Revenue
$487.7M
$260.4M
Net Profit
$-49.3M
$3.5M
Gross Margin
19.9%
Operating Margin
-10.1%
6.5%
Net Margin
-10.1%
1.4%
Revenue YoY
44.7%
-9.4%
Net Profit YoY
-123.2%
-14.3%
EPS (diluted)
$0.39

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
SDHC
SDHC
Q4 25
$487.7M
$260.4M
Q3 25
$496.6M
$262.0M
Q2 25
$477.6M
$223.9M
Q1 25
$462.3M
$224.7M
Q4 24
$337.0M
$287.5M
Q3 24
$331.0M
$277.8M
Q2 24
$356.3M
$220.9M
Q1 24
$346.9M
$189.2M
Net Profit
CLOV
CLOV
SDHC
SDHC
Q4 25
$-49.3M
$3.5M
Q3 25
$-24.4M
$2.1M
Q2 25
$-10.6M
$2.4M
Q1 25
$-1.3M
$2.7M
Q4 24
$-22.1M
$4.1M
Q3 24
$-9.2M
$5.3M
Q2 24
$7.4M
$3.6M
Q1 24
$-19.2M
$3.0M
Gross Margin
CLOV
CLOV
SDHC
SDHC
Q4 25
19.9%
Q3 25
21.0%
Q2 25
23.2%
Q1 25
23.8%
Q4 24
25.5%
Q3 24
24.5%
26.5%
Q2 24
30.3%
26.7%
Q1 24
23.6%
26.1%
Operating Margin
CLOV
CLOV
SDHC
SDHC
Q4 25
-10.1%
6.5%
Q3 25
-4.9%
6.6%
Q2 25
-2.2%
7.7%
Q1 25
-0.3%
8.7%
Q4 24
-6.4%
10.4%
Q3 24
-2.7%
14.2%
Q2 24
2.0%
11.7%
Q1 24
-6.5%
11.3%
Net Margin
CLOV
CLOV
SDHC
SDHC
Q4 25
-10.1%
1.4%
Q3 25
-4.9%
0.8%
Q2 25
-2.2%
1.1%
Q1 25
-0.3%
1.2%
Q4 24
-6.6%
1.4%
Q3 24
-2.8%
1.9%
Q2 24
2.1%
1.7%
Q1 24
-5.5%
1.6%
EPS (diluted)
CLOV
CLOV
SDHC
SDHC
Q4 25
$0.39
Q3 25
$0.24
Q2 25
$0.26
Q1 25
$0.30
Q4 24
$0.50
Q3 24
$0.58
Q2 24
$0.40
Q1 24
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
SDHC
SDHC
Cash + ST InvestmentsLiquidity on hand
$78.3M
$12.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$86.7M
Total Assets
$541.0M
$557.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
SDHC
SDHC
Q4 25
$78.3M
$12.7M
Q3 25
$14.8M
Q2 25
$16.8M
Q1 25
$12.7M
Q4 24
$194.5M
$22.4M
Q3 24
$288.0M
$23.7M
Q2 24
$254.8M
$17.3M
Q1 24
$208.3M
$32.8M
Stockholders' Equity
CLOV
CLOV
SDHC
SDHC
Q4 25
$308.7M
$86.7M
Q3 25
$340.9M
$82.2M
Q2 25
$344.2M
$80.0M
Q1 25
$336.1M
$76.9M
Q4 24
$341.1M
$73.6M
Q3 24
$342.2M
$68.4M
Q2 24
$324.9M
$62.1M
Q1 24
$292.5M
$59.7M
Total Assets
CLOV
CLOV
SDHC
SDHC
Q4 25
$541.0M
$557.6M
Q3 25
$559.7M
$571.6M
Q2 25
$575.0M
$570.2M
Q1 25
$583.7M
$513.9M
Q4 24
$580.7M
$475.9M
Q3 24
$653.0M
$460.1M
Q2 24
$674.2M
$429.3M
Q1 24
$671.8M
$401.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
SDHC
SDHC
Operating Cash FlowLast quarter
$-66.9M
$9.8M
Free Cash FlowOCF − Capex
$-69.0M
$8.7M
FCF MarginFCF / Revenue
-14.1%
3.4%
Capex IntensityCapex / Revenue
0.4%
0.4%
Cash ConversionOCF / Net Profit
2.77×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$-36.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
SDHC
SDHC
Q4 25
$-66.9M
$9.8M
Q3 25
$12.1M
$22.8M
Q2 25
$5.4M
$-28.9M
Q1 25
$-16.3M
$-34.9M
Q4 24
$34.8M
$5.5M
Q3 24
$50.0M
$22.9M
Q2 24
$44.8M
$39.0K
Q1 24
$25.9M
$-9.3M
Free Cash Flow
CLOV
CLOV
SDHC
SDHC
Q4 25
$-69.0M
$8.7M
Q3 25
$11.4M
$21.4M
Q2 25
$4.8M
$-31.1M
Q1 25
$-16.5M
$-35.9M
Q4 24
$33.3M
$4.8M
Q3 24
$49.6M
$22.3M
Q2 24
$44.4M
$-2.1M
Q1 24
$25.5M
$-9.7M
FCF Margin
CLOV
CLOV
SDHC
SDHC
Q4 25
-14.1%
3.4%
Q3 25
2.3%
8.2%
Q2 25
1.0%
-13.9%
Q1 25
-3.6%
-16.0%
Q4 24
9.9%
1.7%
Q3 24
15.0%
8.0%
Q2 24
12.5%
-1.0%
Q1 24
7.3%
-5.1%
Capex Intensity
CLOV
CLOV
SDHC
SDHC
Q4 25
0.4%
0.4%
Q3 25
0.1%
0.5%
Q2 25
0.1%
0.9%
Q1 25
0.0%
0.5%
Q4 24
0.5%
0.2%
Q3 24
0.1%
0.2%
Q2 24
0.1%
1.0%
Q1 24
0.1%
0.2%
Cash Conversion
CLOV
CLOV
SDHC
SDHC
Q4 25
2.77×
Q3 25
10.70×
Q2 25
-12.24×
Q1 25
-13.01×
Q4 24
1.33×
Q3 24
4.28×
Q2 24
6.04×
0.01×
Q1 24
-3.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

SDHC
SDHC

Southeast$164.7M63%
Central$95.8M37%

Related Comparisons